Quantitative assessment of minimal residual disease (MRD) in canine lymphoma by using real-time polymerase chain reaction

Veterinary Immunology and Immunopathology

Volumn 126, Issue 3-4, 2008, Pages 321-331

  Yamazaki, Jumpei ^a   Baba, Kenji ^a   Goto Koshino, Yuko ^a   Setoguchi Mukai, Asuka ^a   Fujino, Yasuhito ^a   Ohno, Koichi ^a   Tsujimoto, Hajime ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Allele specific oligonucleotides; Antification; Canine lymphoma; MRD; Real time PCR

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; GENOMIC DNA; LOMUSTINE; MELPHALAN; OLIGONUCLEOTIDE; PLASMID DNA; PREDNISOLONE; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; VINCRISTINE; VINCRISTINE SULFATE;

ACCURACY; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOG DISEASE; DRUG DOSE REDUCTION; FEMALE; KINETICS; LYMPHOMA CELL; LYMPHOMA CELL LINE; MALE; MINIMAL RESIDUAL DISEASE; NONHUMAN; NUCLEOTIDE SEQUENCE; OLIGONUCLEOTIDE PROBE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REMISSION; SENSITIVITY AND SPECIFICITY; T CELL LYMPHOMA; TUMOR CELL; TUMOR GROWTH;

ANIMALS; CELL LINE, TUMOR; DNA PRIMERS; DOG DISEASES; DOGS; GENES, T-CELL RECEPTOR GAMMA; LYMPHOMA; NEOPLASM, RESIDUAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

CANIS FAMILIARIS;

EID: 56149083521     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetimm.2008.09.004     Document Type: Article

References (38)

1. Bowman A., Jones D., Medeiros L.J., and Luthra R. Quantitative PCR detection of t(14;18) bcl-2/JH fusion sequences in follicular lymphoma patients: comparison of peripheral blood and bone marrow aspirate samples. J. Mol. Diagn. 6 (2004) 396-400
2. Bruggemann M., Droese J., Bolz I., Luth P., Pott C., von Neuhoff N., Scheuering U., and Kneba M. Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR. Leukemia 14 (2000) 1419-1425
3. Bruggemann M., Pott C., Ritgen M., and Kneba M. Significance of minimal residual disease in lymphoid malignancies. Acta Haematol. 112 (2004) 111-119
4. Bruggemann M., Raff T., Flohr T., Gokbuget N., Nakao M., Droese J., Luschen S., Pott C., Ritgen M., Scheuring U., Horst H.A., Thiel E., Hoelzer D., Bartram C.R., and Kneba M. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 107 (2006) 1116-1123
5. Burnett R.C., Blake M.K., Thompson L.J., Avery P.R., and Avery A.C. Evolution of a B-cell lymphoma to multiple myeloma after chemotherapy. J. Vet. Intern. Med. 18 (2004) 768-771
6. Burnett R.C., Vernau W., Modiano J.F., Olver C.S., Moore P.F., and Avery A.C. Diagnosis of canine lymphoid neoplasia using clonal rearrangements of antigen receptor genes. Vet. Pathol. 40 (2003) 32-41
7. Busch K., Borkhardt A., Wossmann W., Reiter A., and Harbott J. Combined polymerase chain reaction methods to detect c-myc/IgH rearrangement in childhood Burkitt's lymphoma for minimal residual disease analysis. Haematologica 89 (2004) 818-825
8. Calzolari C., Gentilini F., Agnoli C., Zannoni A., Peli A., Cinotti S., and Bergamini P.F. PCR assessment of minimal residual disease in 8 lymphoma-affected dogs. Vet. Res. Commun. 30 Suppl. 1 (2006) 285-288
9. Cross N.C., Feng L., Chase A., Bungey J., Hughes T.P., and Goldman J.M. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 82 (1993) 1929-1936
10. Fournel-Fleury C., Magnol J.P., Bricaire P., Marchal T., Chabanne L., Delverdier A., Bryon P.A., and Felman P. Cytohistological and immunological classification of canine malignant lymphomas: comparison with human non-Hodgkin's lymphomas. J. Comp. Pathol. 117 (1997) 35-59
11. Frimberger A.E., Moore A.S., Rassnick K.M., Cotter S.M., O'Sullivan J.L., and Quesenberry P.J. A combination chemotherapy protocol with dose intensification and autologous bone marrow transplant (VELCAP-HDC) for canine lymphoma. J. Vet. Intern. Med. 20 (2006) 355-364
12. Garrett L.D., Thamm D.H., Chun R., Dudley R., and Vail D.M. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J. Vet. Intern. Med. 16 (2002) 704-709
13. Gribben J.G. Monitoring disease in lymphoma and CLL patients using molecular techniques. Best Pract. Res. Clin. Haematol. 15 (2002) 179-195
14. Howard O.M., Gribben J.G., Neuberg D.S., Grossbard M., Poor C., Janicek M.J., and Shipp M.A. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J. Clin. Oncol. 20 (2002) 1288-1294
15. Keller R.L., Avery A.C., Burnett R.C., Walton J.A., and Olver C.S. Detection of neoplastic lymphocytes in peripheral blood of dogs with lymphoma by polymerase chain reaction for antigen receptor gene rearrangement. Vet. Clin. Pathol. 33 (2004) 145-149
16. Kern W., Schoch C., Haferlach T., and Schnittger S. Monitoring of minimal residual disease in acute myeloid leukemia. Crit. Rev. Oncol. Hematol. 56 (2005) 283-309
17. Kraegel S. Cancer-lymphoma. In: SJ Ettinger E.F. (Ed). Textbook of Veterinary Internal Medicine: Disease of the Dog and Cat (2000), WB Saunders Co., Philadelphia 1923
18. Lana S.E., Jackson T.L., Burnett R.C., Morley P.S., and Avery A.C. Utility of polymerase chain reaction for analysis of antigen receptor rearrangement in staging and predicting prognosis in dogs with lymphoma. J. Vet. Intern. Med. 20 (2006) 329-334
19. Lupu M., Sullivan E.W., Westfall T.E., Little M.T., Weigler B.J., Moore P.F., Stroup P.A., Zellmer E., Kuhr C., and Storb R. Use of multigeneration-family molecular dog leukocyte antigen typing to select a hematopoietic cell transplant donor for a dog with T-cell lymphoma. J. Am. Vet. Med. Assoc. 228 (2006) 728-732
20. MacDonald V.S., Thamm D.H., Kurzman I.D., Turek M.M., and Vail D.M. Does l-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma?. J. Vet. Intern. Med. 19 (2005) 732-736
21. Mandigers C.M., Meijerink J.P., Mensink E.J., Tonnissen E.L., Hebeda K.M., Bogman M.J., and Raemaekers J.M. Lack of correlation between numbers of circulating t(14;18)-positive cells and response to first-line treatment in follicular lymphoma. Blood 98 (2001) 940-944
22. Mandigers C.M., Meijerink J.P., Raemaekers J.M., Schattenberg A.V., and Mensink E.J. Graft-versus-lymphoma effect of donor leucocyte infusion shown by real-time quantitative PCR analysis of t(14;18). Lancet 352 (1998) 1522-1523
23. Ovejera, A.A., Houchens, D.P., Barker, A.D., 1977. Sensitivity of a human tumor xenograft in (athymic) nude nice to various clinically-active drugs. In: Second International Workshop Nude Mice, pp. 451-460.
24. Pennell N., Woods A., Reis M., Buckstein R., Spaner D., Imrie K., Hewitt K., Boudreau A., Seth A., and Berinstein N.L. Association of clinical status of follicular lymphoma patients after autologous stem cell transplant and quantitative assessment of lymphoma in blood and bone marrow as measured by SYBR Green I polymerase chain reaction. J. Mol. Diagn. 8 (2006) 40-50
25. Pott C., Schrader C., Gesk S., Harder L., Tiemann M., Raff T., Bruggemann M., Ritgen M., Gahn B., Unterhalt M., Dreyling M., Hiddemann W., Siebert R., Dreger P., and Kneba M. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 107 (2006) 2271-2278
26. Price C.G., Meerabux J., Murtagh S., Cotter F.E., Rohatiner A.Z., Young B.D., and Lister T.A. The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma. J. Clin. Oncol. 9 (1991) 1527-1532
27. Rambaldi A., Lazzari M., Manzoni C., Carlotti E., Arcaini L., Baccarani M., Barbui T., Bernasconi C., Dastoli G., Fuga G., Gamba E., Gargantini L., Gattei V., Lauria F., Lazzarino M., Mandelli F., Morra E., Pulsoni A., Ribersani M., Rossi-Ferrini P.L., Rupolo M., Tura S., Zagonel V., Zaja F., Zinzani P., Reato G., and Foa R. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 99 (2002) 856-862
28. Schreuder M.I., Hoeve M.A., Groothuis L., Boot H., Boerrigter L.H., de Jong D., Veenendaal R.A., Jansen J.H., and van Krieken J.H. Monitoring gastric lymphoma in peripheral blood by quantitative IgH allele-specific oligonucleotide real-time PCR and API2-MALT1 PCR. Br. J. Haematol. 131 (2005) 619-623
29. Shivapurkar N., Stastny V., Takahashi T., Suzuki M., Echebiri C., Reddy J., and Gazdar A.F. Novel real-time PCR assay using a universal molecular marker for diagnosis of hematologic cancers. Int. J. Cancer 116 (2005) 656-660
30. Sykes P.J., Neoh S.H., Brisco M.J., Hughes E., Condon J., and Morley A.A. Quantitation of targets for PCR by use of limiting dilution. Biotechniques 13 (1992) 444-449
31. Trakhtenbrot L., Rechavi G., and Amariglio N. The multiparametric scanning system for evaluation of minimal residual disease in hematological malignancies. Acta Haematol. 112 (2004) 24-29
32. van der Velden V.H., Hochhaus A., Cazzaniga G., Szczepanski T., Gabert J., and van Dongen J.J. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 17 (2003) 1013-1034
33. van der Velden V.H., Wijkhuijs J.M., Jacobs D.C., van Wering E.R., and van Dongen J.J. T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis. Leukemia 16 (2002) 1372-1380
34. van der Velden V.H., Willemse M.J., van der Schoot C.E., Hahlen K., van Wering E.R., and van Dongen J.J. Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR. Leukemia 16 (2002) 928-936
35. Verhagen O.J., Willemse M.J., Breunis W.B., Wijkhuijs A.J., Jacobs D.C., Joosten S.A., van Wering E.R., van Dongen J.J., and van der Schoot C.E. Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia 14 (2000) 1426-1435
36. Vonderhaar M.A., and Morrison W.B. Lymphosarcoma. In: Carroll C.C. (Ed). Cancer in Dogs and Cats: Medical and Surgical Management (1998), The Williams & Wilkins Co., Baltimore 667-695
37. Yang X.Y., Xu D., Du J., Kamino H., Rakeman J., and Ratech H. Rapid detection of clonal T-cell receptor-beta gene rearrangements in T-cell lymphomas using the LightCycler-polymerase chain reaction with DNA melting curve analysis. J. Mol. Diagn. 7 (2005) 81-88
38. Yashima A., Maesawa C., Uchiyama M., Tarusawa M., Satoh T., Satoh M., Enomoto S., Sugawara K., Numaoka H., Murai K., Utsugisawa T., Ishida Y., and Masuda T. Quantitative assessment of contaminating tumor cells in autologous peripheral blood stem cells of B-cell non-Hodgkin lymphomas using immunoglobulin heavy chain gene allele-specific oligonucleotide real-time quantitative-polymerase chain reaction. Leuk. Res. 27 (2003) 925-934